Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. PHVS
9. QQQ
10. UNFI

Go back to Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
SAREPTA THERAP (NASDAQ: SRPT) Delayed: 22.23 +1.29 (6.16%)
Previous Close $20.94    52 Week High $63.73 
Open $20.81    52 Week Low $8.00 
Day High $23.22    P/E N/A 
Day Low $20.63    EPS $-5.69 
Volume 2,368,977